Brain potential signs of slowed stimulus processing following cholecystokinin in Parkinson's disease

Abstract

Data indicate a deleterious rather than beneficial effect of CCK on cognitive processing in PD patients that might result from a prevailing effect of the neuropeptide on transmitter systems (e.g. GABAergic) other than the DA system.

Intranasal delivery: circumventing the iron curtain to treat neurological disorders

“…In healthy controls, CCK-8 enhanced the P3 complex and shortened latencies of the N2 and P3 components of the AEP evoked by task relevant target stimuli. In PD patients, these AEP components were distinctly delayed after CCK-8, while motor performance did not change [82].…”

Event-related potentials and cognition in Parkinson’s disease: An integrative review

“…Notably, ERP measures were negatively affected in the latter studies while substantial motor improvements were observed following drug administration, indicating that P3b might potentially qualify as an objective indicator of the cognitive side effects of dopamine agonists. Moreover, in a more controlled, experimental design P3b latency was surprisingly found to be prolonged in PD patients under the influence of the peptide hormone cholecystokinin, which is thought to increase dopaminergic firing in the basal ganglia (Smolnik et al, 2002).…”

Delayed gastric emptying in Parkinson's disease

“…All 3 have been considered as targets for disease‐modifying therapy in PD. CCK polymorphisms have been reported to confer an increased risk of hallucinations in PD, but therapies targeting CCK have thus far been ineffective . Agonists of the GLP‐1 receptor have been reported to have neuroprotective potential based upon studies in animal models of PD .…”